docwirenews.com
Cure8 news brief
Why This Matters
The trial suggests starting infliximab early can delay the need for further biologic escalation in children with moderate-to-severe Crohn’s disease, and that stopping anti‑TNF after induction often leads to relapse.
Who Should Pay Attention
Pediatric patients with moderate-to-severe Crohn’s disease, parents and caregivers, pediatric gastroenterologists, and researchers studying pediatric IBD treatment strategies.
Study Snapshot
Story typeResearch news
Evidence typePhase 3 clinical trial
Source depthFull source text
What To Know
This is a randomized, multicenter pediatric trial (TISKids) comparing induction with five infliximab infusions then stopping versus conventional induction (exclusive enteral nutrition or prednisolone), with azathioprine maintenance in both arms.
After 5 years almost all patients in both groups required additional Crohn’s disease–related therapy, but those initially given infliximab had a longer median time before restarting biologic therapy.
The trial also found azathioprine monotherapy poorly maintained long-term remission and that stopping anti‑TNF after induction led to frequent need for reinitiation. Perianal complications were observed only in the conventionally treated group in this report.
Practical takeaway: the results support considering early and maintained biologic therapy (rather than short-course induction then stop) in children with moderate-to-severe Crohn’s disease, but most patients still needed further treatment over 5 years.
Keep In Mind
This is a randomized controlled trial (TISKids) with 5-year follow-up. The infliximab arm received five induction infusions and then stopped; many patients later required retreatment. Findings highlight long-term management challenges rather than a cure, and do not replace individualized clinical decisions.
Source Details
Review the original publication for the complete reporting, methods, and context.
Phase 3 clinical trial
Article type assigned from Cure8 classification; confirm details in the original source.
Publicationdocwirenews.com
Indexed viaGoogle News
Source typeWeb article
PublishedSep 29, 2026, 10:02 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Escalating Crohn's Care: The Case for Dual Therapy - Medscape
Combination (dual) therapy is an active area of research because many people with Crohn’s disease don’t achieve lasting remission on a single advanced therapy. New trials suggest some combinations may improve remission...
TNF inhibitors might help prevent serious complications in kids with Crohn's Disease
The study suggests starting anti-TNF drugs early in children with Crohn's could strongly lower the chance of developing anal fistulas, a serious complication that often requires surgery. Preventing fistulas can reduce...
Escalating Crohn’s Care: The Case for Dual Therapy
Researchers and clinicians are increasingly studying combinations of IBD drugs because single‑drug remission rates have plateaued; dual therapy may improve outcomes for patients who have failed prior treatments.